The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis

Neuromuscular Disorders

Volumn 24, Issue 3, 2014, Pages 222-226

  Alfano, L N ^a   Lowes, L P ^a   Dvorchik, I ^a   Yin, H ^a   Maus, E G ^a   Flanigan, K M ^a   Mendell, J R ^a  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

2 min walk test; 6 min walk test; Function; Outcome measure; Sporadic inclusion body myositis

Indexed keywords

2-MIN WALK TEST; 6-MIN WALK TEST; FUNCTION; OUTCOME MEASURE; SPORADIC INCLUSION BODY MYOSITIS;

AGED; AGED, 80 AND OVER; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; TREATMENT OUTCOME; WALKING;

EID: 84894232912     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.11.012     Document Type: Article

References (30)

1. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006, 253(Suppl. 5):V2-V8.
2. Greenberg S.A. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012, 25:630-639.
3. Mastaglia F.L. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol 2009, 28:66-71.
4. Lowes L.P., Alfano L., Viollet L., et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 2012, 45:163-168.
5. Needham M., Corbett A., Day T., Christiansen F., Fabian V., Mastaglia F.L. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci Off J Neurosurg Soc Aust 2008, 15:1350-1353.
6. Arnardottir S., Alexanderson H., Lundberg I.E., Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med Off J UEMS Eur Board Phys Rehabil Med 2003, 35:31-35.
7. Johnson L.G., Collier K.E., Edwards D.J., Philippe D.L., Eastwood P.R., Walters S.E. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009, 10:178-184.
8. Lazarou I.N., Guerne P.A. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 2013, 40(5):550-564.
9. Lloyd T.E. Novel therapeutic approaches for inclusion body myositis. Curr Opin Rheumatol 2010, 22:658-664.
10. Rodino-Klapac L.R., Haidet A.M., Kota J., Handy C., Kaspar B.K., Mendell J.R. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009, 39:283-296.
11. Dalakas M.C., Rakocevic G., Schmidt J., Salajegheh M., McElroy B., Harris-Love M.O. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain J Neurol 2009, 132:1536-1544.
12. Cortese A., Machado P., Morrow J., et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord NMD 2013, 23:404-412.
13. Lindberg C., Oldfors A. Prognosis and prognostic factors in sporadic inclusion body myositis. Acta Neurol Scand 2012, 125:353-358.
14. Rose M.R., McDermott M.P., Thornton C.A., Palenski C., Martens W.B., Griggs R.C. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001, 57:548-550.
15. Mendell J.R., Csimma C., McDonald C.M., et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve 2007, 35:8-16.
16. Casanova C., Celli B.R., Barria P., et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J Off J Eur Soc Clin Respir Physiol 2011, 37:150-156.
17. Jenkins S., Cecins N., Camarri B., Williams C., Thompson P., Eastwood P. Regression equations to predict 6-min walk distance in middle-aged and elderly adults. Physiother Theory Pract 2009, 25:516-522.
18. Learmonth Y.C., Paul L., McFadyen A.K., Mattison P., Miller L. Reliability and clinical significance of mobility and balance assessments in multiple sclerosis. Int J Rehabil Res 2012, 35:69-74.
19. Reuben D.B., Magasi S., McCreath H.E., et al. Motor assessment using the NIH toolbox. Neurology 2013, 80:S65-S75.
20. Griggs R.C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
21. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M.G. Inclusion body myositis: MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010, 20:142-147.
22. Laboratories ATSCoPSfCPF ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
23. Tawil R., McDermott M.P., Mendell J.R., Kissel J., Griggs R.C. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY group. Neurology 1994, 44:442-446.
24. Jackson C.E., Barohn R.J., Gronseth G., Pandya S., Herbelin L. Muscle study G. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008, 37:473-476.
25. Fries J., Rose M., Krishnan E. The PROMIS of better outcome assessment: responsiveness, floor and ceiling effects, and Internet administration. J Rheumatol 2011, 38:1759-1764.
26. Bohannon R.W. Reference values for the timed up and go test: a descriptive meta-analysis. J Geriatr Phys Ther 2006, 29:64-68.
27. Shumway-Cook A., Brauer S., Woollacott M. Predicting the probability for falls in community-dwelling older adults using the timed up and go test. Phys Ther 2000, 80:896-903.
28. du Bois R.M., Weycker D., Albera C., et al. Six-min-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011, 183:1231-1237.
29. Karapolat H., Durmaz B., Nalbantgil S., Durmaz I. Quality of life and functional status in congestive heart failure. Anadolu Kardiyol Derg 2006, 6:327-332.
30. Bohannon R.W. Comfortable and maximum walking speed of adults aged 20-79years: reference values and determinants. Age Ageing 1997, 26:15-19.